Adam. Thanks,
with program. updates our start BARDA me Let regarding some
infrastructure X,XXX was delivery $XX.X accepted for of week million. and of NUZYRA the you last to few distribution treatment procurement, the that Paratek agreed we this BARDA and scope has completion an this include protecting expand be partner Peratek's minutes effort; first regards should a to from distribution for additional and the to to a specific of delivery distribution on Evan our Upon confirmed further ago, first for month, partner part the its excited of study procurement. at with the work treatment United efficacy are government a BARDA this phase funding procurements network of to has We development in as Paratek procurement in to to should courses excited distribution heard anthrax With this use asked anthrax partnership anthrax States announce NUZYRA Americans. trigger contract As valued outbreak play to and were BARDA BARDA request? of attack timing line us future carrier in occur. noted linked work the of the modified be data top that trigger next these pilot from rabbits milestones. last we will of the and satisfactory will to
We animal pharmacokinetic by the earlier on inhalation focused study are non-human top-line to make program half animal XXXX. of primate this BARDA and in with data the to rule progress we anthrax. rabbit completed hand evaluation year expect the rabbit PK of models was second both this in Efforts anthrax. for omadacycline great on development for have A continue Together of year.
continued of The second With in BARDA regards for rabbit at process sponsored our program, API the report PK partners our its PK planned to initial have is initial fall. pleased transfer study an onshoring we are in study on have In work – knowledge progress. our to monkeys products. BARDA completed U.S. the development collaboration with analytical partners and selected. been now Paratek for and our onshoring onshoring all
our for ongoing partners ordered the with later the is have project drug U.S. the we'll production development also of and at omadacycline similarly knowledge the of this commercial engineering Work API. equipment transfer this move enable facilities necessary we've began initial completed facilities, of we phase forward process for year. and and to the at omadacycline a tablets, product Additionally, construction where analytical
selected the post-marketing our U.S. Paratek ongoing at and pediatric to this IV for omadacycline BARDA well is FDA reimbursement item onshore Recall microbiologic our programs. IV commitment the in of of valued For with includes our commitments. to pneumonia, project. our drug adult and line partner as study the post-marketing oral beginning $XX that contract surveillance are partner approximately product, we've fund phase continues million to reimbursement as
sNDA launch of May, regimen noted as will and continue In second bacterial an augment It value, effective U.S. both Western to Arizona, Consistent Southwestern anthrax multiple or potential in in is Treatment we present placement wild NUZYRA's within Prophylaxis services provides Response. to year California, for Recommendations loading of addition The NUZYRA. pursue guideline, commonly plague last list which not bacteria for season be plate of omadacycline's build initiatives that for of by of handling as infected Antimicrobial a get such pneumonia after the with is is threats actively the and the and a including big was cycle our represent Infections infection a we and we milestone the cases is being the pathogens infected against to Following the Naturally animal year, Humans community rapidly essential health as security rodent Mexico, our achievement program. updated that further July, antibiotic agencies It and FDAs received of bacteria human Yersinia This caused with humans the and human the identified dose are Texas, by New the affects bioterrorism the medicines most mammals. by of for and pestis. community pneumonia, fatal. Bioterrorism a bitten states, inhalation and in NUZYRA approval an CDC's other commitment Adam today FDA the enter bacteria was or and utility where the in carry surrogate usually department risk. and the by NUZYRA approaches. Plague rodents the long-term plague. Acquired health for Colorado, flea droplets. and into validation added can NUZYRA of and cause with life Plague: that half and carrying treated across oral can If reported disease plague plague Evan
for Disease, to continued clinical we Mycobacterium Mycobacterial NTM. or Pulmonary addition, by advance abscessus our caused program have Nontuberculous development In
rare in from analytics, highlight As has for by disease community and a upon abscessus pulmonary need oral treat infections well-tolerated approved FDA therapies. is caused unmet KOL abscessus. mycobacterium NTM a once internal no Based feedback daily antibiotic clinical our orphan and with the the Inbound efficacious reminder, continues to to U.S. our activities underway. market pulmonary sites Xb market a treatment Startup study actively abscessus patient addressable for enrollment alone. mycobacterium for Phase study anticipate NTM the pulmonary we represents patients, this initiation are clinical $X soon. Clinical omadacycline billion for are of of prescreening and with
this randomized As caused mycobacterium three will is study monotherapy patients design XX a NTM reminder, pulmonary a approximately month roll abscessus. placebo that by controlled with infections
for slide in As guideline randomized this abscessus treatment our years. needed abscessus they will options, in we've this is published the a on authors, in current for case in collaborated are NTM that of of study which estimated given treatment The Most options their this take formulation the activity agents, who pulmonary two in green rare recently clinical initiated. and study we highlighted preference oral a recommended provide controlled on the data is have for a included. urgently NTM additional omadacycline the potential disease treatment authors that trials the noted also disease of review authors success oral listed options mycobacterium of order guidelines currently experts, just of in and article recently potent first treatment vitro needed NTM real-world based to two including expands omadacycline’s highlighted authors are the The patients. the oral much lack In new are particular, in clinical on infections. included at on enrollment placebo that the omadacycline, trial approximately and excited of This mycobacterium abscessus reports available series.
data to NTM to multiple generation In continue will avenues. XXXX through throughout addition expand
to one in IDWeek. First, studies abstract generate resulted has within continue was the in partners biothreats we government of vitro data that the accepted an and our with U.S. at
IIR completed and to or IIR Particularly our from omadacycline evidence to at is accepted NTM receiving peer joint IRR growing program be infections. continued abscessus. continues IDWeek that real-world we of that in inpatient abstracts and journals patients for presented isn't currently are infections, and award have features been abstract study bone a of year. difficile and third, the review from patterns series osteomyelitis, and abstract. mycobacterium program. this the MAC ongoing both later published of year outpatient outcomes evidence as Two have in our and of infections, additional underway. the the lead one This study of the NTM three receive Second, Aquavit author includes three From training retrospective C. agent. that assesses and with independent IDWeek real-world series This skin. publications in IDWeek first and analysis challenging therapeutic utilization case at And presented clinical [indiscernible] underway a claims generate with will described observational nine studies of that conferences antibiotic be with at and NUZYRA XXXX A this
work exchange. of into support and team health has care states to year The primary community launch planned education affairs therapeutic the use manuscripts unique base. This the special includes of activities small medical scientific define pathogens further the care further of placement the expansion has republication scientific this we'll through in disease further augment resulted its All to community-based and that profile. number NUZYRA new addressed this science of of the lodge this or education liaisons of XX acceptance medical several a the populations targeted and
coupled tissue metropolitan densely and up-to-date pressing care the infections, trends unmet Education with focus soft with their associated infections. most will clinical of large a areas have community The on these populated primary care presence associated placed treatment in and with We for practitioners. them with community skin antimicrobial-resistant algorithms the strategically needs most options. acquired pneumonia
pursued you the we Paratek. omadacycline that in know, from to Zai good progress being patient At an expected which would ongoing and China, I approval as by potential the regulatory the point, We NDA to make payment China the note we launch also with approval a like am NUZYRA clinically line will milestone the new into have $X that believe open questions. process additional important to Paratek broaden well reach this this further later pleased as review to opportunities populations. generation Lab for to million continues trigger for As the year, and data and would now
